17 January 2018
News and Views
Links and Services
Active injecting drug users are more likely to fail treatment for genotype 2/3 hepatitis C and require additional support, find researchers in Liver International.
Genotype 2/3 hepatitis C virus (HCV) has a good response to treatment with peginterferon and riba
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors